Clinical data | |
---|---|
Trade names | Ranexa, Aspruzyo Sprinkle, Corzyna |
AHFS/Drugs.com | Monograph |
MedlinePlus | a606015 |
License data |
|
Routes of administration | By mouth |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | 35 to 50% |
Protein binding | ~62% |
Metabolism | Extensive in liver (CYP3A, CYP2D6) and intestine |
Elimination half-life | 1.4 to 1.9 hours[4] |
Excretion | Kidney (75%) and fecal (25%) |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
ChEBI | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.149.259 |
Chemical and physical data | |
Formula | C24H33N3O4 |
Molar mass | 427.545 g·mol−1 |
3D model (JSmol) | |
Chirality | Racemic mixture |
| |
| |
(what is this?) (verify) |
Ranolazine, sold under the brand name Ranexa among others, is a medication used to treat heart related chest pain.[5] Typically it is used together with other medications when those are insufficient.[5][6] Therapeutic benefits appear smaller in females than males.[5] It is taken by mouth.[5]
Common side effects include constipation, headache, nausea, and dizziness.[5] Serious side effects may include QT prolongation.[5] Ranolazine is contraindicated (not recommended) in those with liver cirrhosis.[5] How it works is not clear but may involve adenosine triphosphate.[5]
Ranolazine was approved for medical use in the United States in 2006.[5] In 2021, it was the 202nd most commonly prescribed medication in the United States, with more than 1 million prescriptions.[7][8]